Long standing DADS preceding AL amyloidosis: A sentinel event or serendipitous association?

Vaxman I, Gertz M. When to Suspect a Diagnosis of Amyloidosis. AHA 2020;143:304–11. https://doi.org/10.1159/000506617.

Karam C, Moshe-Lilie O, Chahin N, Ragole T, Medvedova E, Silbermann R. Diagnosis of paraproteinemic neuropathy: Room for improvement. J Neurol Sci 2020;415:116902. https://doi.org/10.1016/j.jns.2020.116902.

Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615–20. https://doi.org/10.1212/wnl.54.3.615.

Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 2010;15:185–95. https://doi.org/10.1111/j.1529-8027.2010.00278.x.

Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol 2020;95:848–60. https://doi.org/10.1002/ajh.25819.

Zingone A, Kuehl WM. Pathogenesis of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Progression to Multiple Myeloma. Semin Hematol 2011;48:4–12. https://doi.org/10.1053/j.seminhematol.2010.11.003.

Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology 2012;2012:595–603. https://doi.org/10.1182/asheducation.V2012.1.595.3798563.

Duston MA, Skinner M, Anderson J, Cohen AS. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med 1989;149:358–60.

Kaku M, Berk JL. Neuropathy Associated with Systemic Amyloidosis. Semin Neurol 2019;39:578–88. https://doi.org/10.1055/s-0039-1688994.

Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998;104:232–7. https://doi.org/10.1016/s0002-9343(98)00037-0.

Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 2011;18:604–10. https://doi.org/10.1111/j.1468-1331.2010.03215.x.

Traynor AE, Gertz MA, Kyle RA. Cranial neuropathy associated with primary amyloidosis. Ann Neurol 1991;29:451–4. https://doi.org/10.1002/ana.410290421.

Adams D, Lozeron P, Theaudin M, Denier C, Fagniez O, Rerat K, et al. Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid 2011;18:98–100. https://doi.org/10.3109/13506129.2011.574354036.

Cheng RR, Eskandari R, Welsh CT, Varma AK. A case of isolated amyloid light-chain amyloidosis of the radial nerve. J Neurosurg 2016;125:598–602. https://doi.org/10.3171/2015.10.JNS151095.

Mathis S, Magy L, Diallo L, Boukhris S, Vallat J-M. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012;45:26–31. https://doi.org/10.1002/mus.22229.

Li J, Li Y, Chen H, Xing S, Feng H, Liu D, et al. Autonomic Neuropathy and Albuminocytologic Dissociation in Cerebrospinal Fluid As the Presenting Features of Primary Amyloidosis: A Case Report. Front Neurol 2017;8. https://doi.org/10.3389/fneur.2017.00368.

Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clin Proc 2017;92:838–50. https://doi.org/10.1016/j.mayocp.2017.02.003.

Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer Journal 2018;8:1–8. https://doi.org/10.1038/s41408-018-0080-9.

Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24. https://doi.org/10.1038/leu.2008.307.

Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7. https://doi.org/10.1038/leu.2010.60.

Rögnvaldsson S, Turesson I, Björkholm M, Landgren O, Kristinsson SY. Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases. Blood 2019;134:5444–5444. https://doi.org/10.1182/blood-2019-131514.

Enqvist S, Mellqvist U-H, Mölne J, Sletten K, Murphy C, Solomon A, et al. A father and his son with systemic AL amyloidosis. Haematologica 2009;94:437–9. https://doi.org/10.3324/haematol.13640.